CG Oncology (CGON) EBT Margin (2023 - 2026)
CG Oncology's (CGON) quarterly EBT Margin came in at 40904.25% in Q1 2026, up 19326498.0% YoY from N/an in Q1 2025, and down 2217.93% on a QoQ basis from 1764.69% in Q4 2025.
CG Oncology (CGON) EBT Margin (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of EBT Margin data on file, last reported at 40904.25% in Q1 2026.
- Quarterly EBT Margin rose 19326498.0% year-over-year to 40904.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17088.9% (up 5891760.0% YoY) and the FY2025 annual result came in at 8895.74%, up 832963.0% from the prior year.
- EBT Margin slipped to 40904.25% in Q1 2026, from 1764.69% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1764.69% in Q4 2025 to a low of 1655100.0% in Q4 2023.
- A 4-year average of 245793.82% and a median of 46903.4% in 2024 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 164811228 bps in 2024, down 28167080 bps in 2024.
- Tracing CGON's EBT Margin over 4 years: stood at 1655100.0% in 2023, then jumped by 100 bps to 6987.72% in 2024, then surged by 75 bps to 1764.69% in 2025, then slumped by 2218 bps to 40904.25% in 2026.
- The last three EBT Margin figures came in at 40904.25% (Q1 2026), 1764.69% (Q4 2025), and 14071.67% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | -40,250.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40,250.56% |
| Mar 31, 2026 | -40,904.25% |
| Dec 31, 2025 | -1,764.69% |
| Sep 30, 2025 | -14,071.67% |
| Mar 31, 2025 | -234,169.23% |
| Dec 31, 2024 | -6,987.72% |
| Sep 30, 2024 | -412,993.02% |
| Jun 30, 2024 | -154,904.50% |
| Mar 31, 2024 | -46,903.40% |
| Dec 31, 2023 | -1,655,100.00% |
| Sep 30, 2023 | -131,322.22% |
| Mar 31, 2023 | -4,611.34% |